Wockhardt: committed to R&D

Wockhardt: committed to R&D

Wockhardt opens $40m unit in Dubai

September 1, 2018

Wockhardt, a global pharmaceutical company, has expanded into the Middle East with the opening of a $40 million state-of-the-art facility for manufacturing new chemical entities (NCEs) in Jebel Ali Free Zone (Jafza) in Dubai, UAE.

Speaking at the inauguration of the new facility, Dr Habil Khorakiwala, founder chairman of Wockhardt, said the company is poised to make a major breakthrough in the development of antimicrobial drugs to fight the emerging threat of superbugs.

“With Wockhardt’s commitment to R&D, we have five breakthrough NCEs that have been accorded Qualified Infectious Disease Product (QIDP) status by US FDA. With the new facility in the Middle East, we aim to focus on our commitment in developing medicines that can fight antimicrobial resistance,” said Dr Khorakiwala.

Antimicrobial Resistance (AMR) – the ability of infections to resist antibiotics to work against it – is increasingly recognised as a growing global health problem. Infections caused by antimicrobial-resistant strains of bacteria – also called ‘superbugs’ – are unlikely to respond to standard treatments resulting in prolonged illness and a greater risk to health, and severely impacting clinical outcomes, leading to further higher healthcare costs due to consumption of healthcare resources.

Dr Mahesh Patel, chief scientific officer of New Drug Discovery, Wockhardt said: “Wockhardt’s drug discovery program has immensely benefited from global collaborations with universities and scientists of international repute in the areas of public health, Infectious diseases and clinical microbiology”.

Wockhardt currently has five novel antibiotic drugs in advanced stages of global clinical development which will be effective against these “superbugs” threats identified by the Center of Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDA has granted Qualified Infectious Disease Program (QIDP) status to the five novel antibiotic drugs.

“Wockhardt has dedicated significant resources for the discovery and development of these novel antibiotics, which are in advanced stages of development are a culmination of 20 years of dedicated and focused research,” said Dr Murtaza Khorakiwala, managing director of Wockhardt.

The 10,000-sq-m facility in Dubai is equipped with best-in-class and fully automated manufacturing equipment, creating a self-sufficient environment for handling, warehousing, manufacturing operations, product testing and product stability.

“The facility will work on the exhibit batches and will be offered for inspection by the regulators at an appropriate time,” he added.

The facility meets the needs of Aseptic Dry Powder Injectable manufacturing and filling with a high-quality operation. This facility is dedicated to launch its novel New Chemical Entities in the antibiotics segment to the world from UAE.

More Stories